Paul Baas

Leiden University — Netherlands

Medicine · Health Sciences

83h-index44.6kcitations547works8.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Occupational and environmental lung diseases(244), Lung Cancer Treatments and Mutations(143), Pleural and Pulmonary Diseases(127), Lung Cancer Diagnosis and Treatment(96), Cancer Immunotherapy and Biomarkers(80)

Publications539 total

Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)
European Journal of Cancer·2025Open Access
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
The Lancet Oncology·2025· 1 cited
P1.07.41 Exhaled Breath Analysis in Patients With Resectable NSCLC Treated With Neoadjuvant Immune Checkpoint Inhibitors
Journal of Thoracic Oncology·2025
Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma
Lung Cancer·2025
Pleural mesothelioma
Nature Reviews Disease Primers·2025· 6 cited
WITHDRAWN: Properties of CD8 T cell recognized neoantigens in different tumor types
Immuno-Oncology Technology·2025Open Access
Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer
Nature Cancer·2025· 18 citedOpen Access
Properties of CD8 T-cell-recognized neoantigens in different tumor types
Immuno-Oncology Technology·2025Open Access
The Predictive and Prognostic Value of T- and B-cell Transcriptomic Signatures for Clinical Response to Immune Checkpoint Blockade in Pleural Mesothelioma
2025· 1 citedOpen Access
Retreatment With Nivolumab and Ipilimumab in Pleural Mesothelioma Following Disease Progression After a Durable Response: Case Series
JTO Clinical and Research Reports·2025Open Access
246P: Optimizing immune checkpoint blockade in pleural mesothelioma by targeting immune evasion: A systems biology approach
Journal of Thoracic Oncology·2025· 1 citedOpen Access
Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiative
Future Oncology·2025· 2 citedOpen Access
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project
JCO Precision Oncology·2025· 1 cited
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Journal of Clinical Oncology·2025· 66 citedOpen Access
34 Monitoring response to immunotherapy in lung cancer using cell-free DNA fragmentomes
Regular and Young Investigator Award Abstracts·2024Open Access
OA01.05 Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up
Journal of Thoracic Oncology·2024· 1 citedOpen Access
Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018: a nationwide population-based cohort study
Acta Oncologica·2024· 5 citedOpen Access
First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?
Lung Cancer·2024
Immune checkpoint inhibition in early-stage non-small cell lung cancer
Lung Cancer·2024· 6 citedOpen Access
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study
The Lancet Oncology·2024· 13 citedOpen Access
page 1 of 27Next →

Frequent Co-authors

Young Tae Kim(24), Paul Van Schil(24), Valerie W. Rusch(23), Wilfried Eberhardt(22), Hisao Asamura(22), Andrew G. Nicholson(22), Ramón Rami–Porta(21), Anna K. Nowak(21), Hedy L. Kindler(20), Harvey I. Pass(20), Kari Chansky(19), Françoise Galateau-Sallé(19), Jan P. van Meerbeeck(19), William D. Travis(18), John Crowley(17), Vanessa Bolejack(17), R. Guijarro(17), Lynn Shemanski(17), Ming‐Sound Tsao(17), David Ball(16)